APL-130277

After a strong 2017, biotech stocks are on track to end the year in the red despite a record 59 new molecular entity approvals, some noteworthy M&A deals and several breakthrough developments in drug discovery and research. Will the new year mark a reversal in fortunes for these firms? Here...